Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.
about
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes malesReducing vascular events risk in patients with dyslipidaemia: an update for cliniciansCurrent role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseApproach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetesFaçons d’identifier et de prendre en charge la dyslipidémie athérogène: Une conséquence métabolique de l’obésité et du diabète.
P2860
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@ast
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@en
type
label
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@ast
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@en
prefLabel
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@ast
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@en
P2860
P1476
Impact of Fenofibrate on Type ...... Subgroup Analysis From FIELD.
@en
P2093
Michel P Hermans
P2860
P304
P356
10.2174/157340310791162686
P577
2010-05-01T00:00:00Z